IRIS
DE PLACIDO, SABINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.324
EU - Europa 4.164
AS - Asia 2.626
AF - Africa 150
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 6
SA - Sud America 6
Totale 14.285
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.162
IT - Italia 1.719
SG - Singapore 1.469
CN - Cina 971
NL - Olanda 515
UA - Ucraina 448
FI - Finlandia 386
DE - Germania 319
IE - Irlanda 301
SE - Svezia 170
CA - Canada 154
CI - Costa d'Avorio 138
GB - Regno Unito 119
IN - India 88
FR - Francia 84
VN - Vietnam 52
IR - Iran 18
BE - Belgio 14
SI - Slovenia 14
CZ - Repubblica Ceca 12
ES - Italia 10
DK - Danimarca 9
EU - Europa 8
BZ - Belize 5
RS - Serbia 5
AU - Australia 4
BG - Bulgaria 4
BR - Brasile 4
HK - Hong Kong 4
JO - Giordania 4
JP - Giappone 4
PK - Pakistan 4
RU - Federazione Russa 4
EG - Egitto 3
MA - Marocco 3
MK - Macedonia 3
PL - Polonia 3
CH - Svizzera 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
KE - Kenya 2
LI - Liechtenstein 2
ME - Montenegro 2
MX - Messico 2
MY - Malesia 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PT - Portogallo 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
AT - Austria 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CL - Cile 1
EC - Ecuador 1
ID - Indonesia 1
IL - Israele 1
LT - Lituania 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
PR - Porto Rico 1
RO - Romania 1
SA - Arabia Saudita 1
TN - Tunisia 1
TW - Taiwan 1
ZA - Sudafrica 1
Totale 14.285
Salva come PNG Salva come JPEG
Città #
Chandler 1.280
Singapore 1.224
Millbury 509
Amsterdam 506
Jacksonville 496
Santa Clara 440
Princeton 368
Naples 343
Ashburn 314
Napoli 258
Nanjing 252
Beijing 241
Wilmington 196
Boston 148
Ottawa 142
Des Moines 118
Nanchang 87
Lawrence 67
Shenyang 59
Tianjin 59
Cagliari 56
Hebei 56
Boardman 53
Dong Ket 52
Pune 51
Woodbridge 49
Milan 48
Changsha 46
Rome 46
Dublin 45
Jiaxing 41
Norwalk 41
Falls Church 39
Houston 34
Kunming 32
Munich 32
Washington 29
Dallas 24
Kronberg 24
Redwood City 23
Seattle 23
Helsinki 22
Los Angeles 17
Ann Arbor 16
Caserta 15
Casoria 15
Hicksville 15
Dearborn 14
Indiana 13
Leawood 13
Fairfield 12
Formia 12
San Mateo 12
Lanzhou 11
New York 10
Pomigliano d'Arco 10
Palermo 9
Salerno 9
Shanghai 9
Augusta 8
London 8
Mountain View 8
Cookstown 7
Olomouc 7
Redmond 7
Sciacca 7
Toronto 7
Torre Annunziata 7
Angri 6
Ardabil 6
Changchun 6
Kolkata 6
Mumbai 6
San Jose 6
Springfield 6
Villarosa 6
Belize City 5
Brescia 5
Cisterna Di Latina 5
Duncan 5
Edinburgh 5
Genoa 5
Lappeenranta 5
Palma Campania 5
Torino 5
Afragola 4
Amman 4
Battipaglia 4
Bologna 4
Brindisi 4
Brno 4
Brussels 4
Buffalo 4
Campobasso 4
Florence 4
Fucecchio 4
Fuzhou 4
Genova 4
Hasselt 4
Macerata Campania 4
Totale 8.404
Salva come PNG Salva come JPEG
Nome #
GIM3-FATA first adjuvant trial on all aromatase inhibitors in early breast cancer. Studio di fase III di coonfronto tra anastrazolo, letrozolo ed exemestane e tra strategia sequenziale (2 anni di terapia con tamoxifene seguiti da tre anni di terapia con inibitori delle aromatasi) verso strategia up-front (5 anni di terapia con inibitori delle aromatasi) nel trattamento adiuvante del carcinoma mammario ormono-responsivo 238
Manuale di Oncologia Clinica 101
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 94
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 91
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 82
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility 79
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 74
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 67
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 66
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 66
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 65
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. 64
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. 63
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 63
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 61
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 58
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? 57
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 55
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 55
Management of patients with BRCA1/2-associated breast cancer 55
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. 54
A comprehensive outlook on inracerebral therapy of malignant gliomas 54
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 53
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 53
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 53
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 53
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 52
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 50
A third-line sorafenib aftrer sequential therapy with sunitinib and mTOR inhibitors in methastatic renal cell carcinoma 50
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 50
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 50
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 50
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 50
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 49
Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues 49
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 49
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis 49
Combination of docetaxel and cetuximab for penile cancer 48
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer 48
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 48
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 48
Non-AIDS-related Kaposi's sarcoma: A single-institution experience 47
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 47
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 47
Akt activation correlates with adverse outcome in tongue cancer. 47
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. 47
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 47
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: A retrospective study 47
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 47
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 47
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 47
Pegylated liposomal doxorubicin in stage IVB mycosis fungoides 46
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 46
COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. 46
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. 46
Approaches for targeting cancer stem cells drug resistance 46
Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new? 45
New perspectives in the therapy of castration resistant prostate cancer. 45
A novel neural network-based survival analysis model. 45
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 45
Reti dinamiche di apprendimento a distanza 45
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 45
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 45
Accanimento terapeutico 45
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 45
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 45
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 45
Randomised multicentre phase III study comparing weekly versus every-3-week carboplatin plus paclitaxel in patients with advanced ovarian cancer: the MITO-7 (Multicentre Italian Trials in Ovarian cancer) -ENGOT-OV-10 (European Network of Gynaecological Oncological Trial Groups) -GCIG (Gynecologic Cancer InterGroup) trial. 44
Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. 44
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 44
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 44
A Metanalysis on the Interaction between HER2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer 44
Bevacizumab as 4th line treatment in metastatic colorectal cancer 44
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 44
Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer 44
The importance of using strain derived criteria for detection of subclinical cardiotoxicity in breast cancer patients undergoing anthracycline and trastuzumab 44
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 44
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 44
Peg-filgrastim and cabazitaxel in prostate cancer patients 43
EGFR mutational status in penile cancer 43
ANTITUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. 43
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. 43
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 43
A banking strategy toward customized therapy in breast cancer. 43
Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? 43
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 43
Biomarkers in localized prostate cancer 43
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 43
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. 42
Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. 42
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. 42
Castration-resistant prostate cancer: current and emerging treatment strategies 42
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 42
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 42
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 42
The influence of prednisone on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer 42
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 42
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 42
Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study 41
MANAGEMENT OF GYNAECOMASTIA IN PATIENTS WITH PROSTATE CANCER: A SYSTEMATIC REVIEW. 41
Totale 5.225
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.405
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.405
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020712 0 0 0 0 0 45 20 50 24 133 201 239
2020/20211.360 33 84 159 123 135 228 118 36 172 33 157 82
2021/20222.383 38 8 23 17 44 74 27 97 317 215 560 963
2022/20233.378 471 224 111 227 377 371 31 299 486 540 184 57
2023/20242.312 71 356 359 179 106 230 28 271 35 63 405 209
2024/20252.219 686 790 59 183 326 175 0 0 0 0 0 0
Totale 14.881